OpGen Inc (OPGN)

NASDAQ
0.557
-0.030(-5.12%)
After Hours
0.580
+0.023(+4.129%)
- Real-time Data
  • Volume:
    586,688
  • Day's Range:
    0.550 - 0.612
  • 52 wk Range:
    0.310 - 3.720

OPGN Overview

Prev. Close
0.587
Day's Range
0.55-0.612
Revenue
4.1M
Open
0.611
52 wk Range
0.31-3.72
EPS
-0.76
Volume
586,688
Market Cap
26.93M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
409,302
P/E Ratio
-0.773
Beta
-0.34
1-Year Change
-77.34%
Shares Outstanding
48,326,942
Next Earnings Date
Nov 09, 2022
What is your sentiment on OpGen?
or
Market is currently closed. Voting is open during market hours.

OpGen Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

OpGen Inc Analysis

OpGen Inc Company Profile

OpGen Inc Company Profile

Employees
95

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company’s products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • run run sell out , i love 60k with Curetis when they tie up merger with OpGen ...pity , i advise as a friend to friend sell out before to be late.
    2
    • We’ll be surprised that one morning this stock will fly to the moon.🥂
      1
      • Following successful completion of Phase 1, Ares Genetics has now entered into Phase 2 of its collaboration with a leading U.S. CRO and reference lab, gaining access to 1,000 proprietary clinical isolates from key pathogensARESdb contents has grown by more than 40% in a yearROCKVILLE, Md., Dec. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that its subsidiary, Ares Genetics (Ares), has successfully completed Phase 1 of its collaboration with a leading U.S. CRO and reference lab, originally announced in August. During Phase 2, Ares will gain access to 1,000 proprietary genome and AST datasets thereby strategically enriching ARESdb with proprietary data for key pathogens.Antimicrobial resistance (AMR) is a growing threat to public health believed to be causing 700,000 fatalities globally each year and bill
        0
        • to the moon
          0
          • This is worse than pump and dump. I will in if this will reach at 0.99/share
            1
            • can anyone tell me why this is abl buy
              0
              • Hodling with diamonds.
                0
                • Yeah they want us to sell so when the price is dip those manipulators will buy.😀. So, I would say, let them down the price, don’t buy for now. Just wait, if they want it at the very low price then let it be. Don’t buy and don’t sell either. 💪💪
                  0
                  • Manipulation by short hedge funds. No worries.
                    0
                    • gonna 🚀 fir Thursday-Frfiday premarget, and then this will get to high 4's, at least. buyin more.
                      0